UroGen Pharma/$URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Ticker
$URGN
Sector
Primary listing
Employees
291
Headquarters
Website
UroGen Pharma Metrics
BasicAdvanced
$898M
-
-$3.19
1.37
-
Price and volume
Market cap
$898M
Beta
1.37
52-week high
$30.00
52-week low
$3.42
Average daily volume
843K
Financial strength
Current ratio
4.008
Quick ratio
3.308
Long term debt to equity
-121.672
Total debt to equity
-123.336
Interest coverage (TTM)
-8.14%
Profitability
EBITDA (TTM)
-124.556
Gross margin (TTM)
88.66%
Net profit margin (TTM)
-139.81%
Operating margin (TTM)
-113.73%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-32.10%
Return on equity (TTM)
268.63%
Valuation
Price to revenue (TTM)
8.082
Price to book
-8.45
Price to tangible book (TTM)
-8.45
Price to free cash flow (TTM)
-5.452
Free cash flow yield (TTM)
-18.34%
Free cash flow per share (TTM)
-3.382
Growth
Revenue change (TTM)
21.45%
Earnings per share change (TTM)
7.81%
3-year revenue growth (CAGR)
19.49%
3-year earnings per share growth (CAGR)
-12.81%
10-year earnings per share growth (CAGR)
-5.94%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $898M as of March 14, 2026.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of March 14, 2026.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.